This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma

This study has been completed.
Information provided by (Responsible Party):
Craig Hofmeister, Ohio State University Comprehensive Cancer Center Identifier:
First received: September 12, 2005
Last updated: June 9, 2015
Last verified: June 2015
This study will assess the ability of Doxorubicin, Vincristine and Dexamethasone plus arsenic trioxide to achieve an overall response rate of greater than 60%.

Condition Intervention Phase
Multiple Myeloma Drug: Doxil® Drug: Vincristine Drug: Dexamethasone Drug: Arsenic Trioxide Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Pegylated Liposomal Doxorubicin (Doxil), Vincristine, and Dexamethasone (DVd) in Combination With Arsenic Trioxide (Trisenox) in Untreated Patients With Symptomatic Multiple Myeloma

Resource links provided by NLM:

Further study details as provided by Craig Hofmeister, Ohio State University Comprehensive Cancer Center:

Primary Outcome Measures:
  • Assess the ability of DVd plus arsenic trioxide to achieve an overall response (complete and partial) rate in patients with untreated Multiple myeloma(MM) [ Time Frame: 2004-2008 ]

Enrollment: 12
Study Start Date: July 2004
Study Completion Date: August 2008
Primary Completion Date: September 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Doxil®
    40 mg/m2 IV day 1
    Other Name: Doxorubicin HCL liposome injection
    Drug: Vincristine
    1.4 mg/m2 (maximum 2 mg) IV day 1
    Other Name: Oncovin
    Drug: Dexamethasone
    40 mg PO days 1-4
    Other Name: DVd
    Drug: Arsenic Trioxide
    0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
    Other Name: Trisenox, ATO
Detailed Description:

Rationale: The chemotherapy combination of doxorubicin, vincristine and dexamethasone (DVd) has been used with some efficacy in patients with multiple myeloma. However, DVd's efficacy is primarily considered palliative for patients with this condition. The current study adds arsenic trioxide to the DVd combo to assess if all of the treatments together improve patient outcomes. Previous studies suggest that arsenic trioxide may enhance the efficacy of specific chemotherapy agents including those in DVd; however, research in people has not yet demonstrated this improved effectiveness. Because the safety of arsenic trioxide has been tested in this patient population, this phase II study will gather more information about safety and also measure efficacy through various measures.

Purpose: This study will evaluate the safety and efficacy of doxorubicin, vincristine and dexamethasone plus arsenic trioxide in untreated patients with symptomatic multiple myeloma. The biology of the tumor and other molecular changes will also be assessed in patients through collections of blood and marrow samples.

Treatment: Patients in this study will receive arsenic trioxide, doxorubicin, vincristine and dexamethasone. During the first five days of the study, patients will be given arsenic trioxide each day through an intravenous infusion. No treatments will be provided on days six and seven. After this first week, patients will then receive study drugs on the following schedule every four weeks: doxorubicin and vincristine on day one, dexamethasone on days one through four, and arsenic trioxide twice each week. This schedule can be repeated up to four times for a total of approximately four months. Several tests and exams will be given throughout the study to closely monitor patients. Supportive care will be provided to help regulate side effects from study drugs and maintain quality of life in patients. Treatments will be discontinued due to disease growth or unacceptable side effects.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must have Multiple Myeloma
  • No prior chemotherapy, thalidomide, or corticosteroids treatments for Multiple Myeloma
  • ECOG performance status must be 0-2

Exclusion Criteria:

  • Resting left ventricular cardiac ejection fraction ≥50% by echo or MUGA scan.
  • QT interval ≥480 msec on baseline ECG.
  • No history of cardiac disease.
  • Pregnant or breast-feeding.
  • No history of hypersensitivity reactions attributed to a conventional formulation of doxorubicin HCL or the components of Doxil.
  • History of prior or concurrent malignancy or myelodysplasia.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00201695

United States, Ohio
Ohio State University
Columbus, Ohio, United States, 43210
Sponsors and Collaborators
Ohio State University Comprehensive Cancer Center
Principal Investigator: Craig Hofmeister, MD Ohio State University
  More Information

Additional Information:
Responsible Party: Craig Hofmeister, Principal Investigator, Ohio State University Comprehensive Cancer Center Identifier: NCT00201695     History of Changes
Other Study ID Numbers: OSU-0354
Study First Received: September 12, 2005
Last Updated: June 9, 2015

Keywords provided by Craig Hofmeister, Ohio State University Comprehensive Cancer Center:
Untreated Patients

Additional relevant MeSH terms:
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Dexamethasone acetate
Liposomal doxorubicin
Arsenic trioxide
BB 1101
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on August 16, 2017